Patten & Patten Inc. TN Has $4.78 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Patten & Patten Inc. TN boosted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 49.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,241 shares of the medical device company's stock after purchasing an additional 23,568 shares during the period. Patten & Patten Inc. TN's holdings in DexCom were worth $4,776,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom in the second quarter worth approximately $25,000. Sachetta LLC lifted its position in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after purchasing an additional 171 shares during the period. Crewe Advisors LLC acquired a new stake in DexCom in the first quarter worth approximately $29,000. Riverview Trust Co increased its holdings in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after buying an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC increased its holdings in shares of DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock valued at $43,000 after buying an additional 315 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Raymond James dropped their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. upped their price target on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. BTIG Research dropped their price target on DexCom from $156.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, July 26th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. Finally, Oppenheimer cut their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and an average price target of $104.59.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 426 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Sadie Stern sold 426 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Up 1.0 %

Shares of NASDAQ DXCM traded up $0.73 during mid-day trading on Monday, reaching $70.69. The company had a trading volume of 2,192,668 shares, compared to its average volume of 3,899,459. The stock has a market capitalization of $27.61 billion, a PE ratio of 42.54, a price-to-earnings-growth ratio of 2.15 and a beta of 1.17. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock's 50 day moving average is $69.66 and its 200-day moving average is $93.10. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.